Heron Therapeutics (HRTX) News Today → Elon’s New Device is About to Shock the World (From InvestorPlace) (Ad) Free HRTX Stock Alerts $3.20 -0.02 (-0.62%) (As of 05/17/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 17 at 10:10 AM | marketbeat.comHeron Therapeutics, Inc. (NASDAQ:HRTX) Expected to Post FY2026 Earnings of $0.20 Per ShareHeron Therapeutics, Inc. (NASDAQ:HRTX - Free Report) - Equities researchers at Capital One Financial upped their FY2026 earnings estimates for shares of Heron Therapeutics in a research note issued on Wednesday, May 15th. Capital One Financial analyst T. Chiang now expects that the biotechnologyMay 16 at 8:42 AM | marketbeat.comHeron Therapeutics (NASDAQ:HRTX) Receives Buy Rating from Needham & Company LLCNeedham & Company LLC restated a "buy" rating and set a $5.00 price objective on shares of Heron Therapeutics in a research report on Thursday.May 16 at 8:09 AM | marketbeat.comHeron Therapeutics, Inc. (NASDAQ:HRTX) Short Interest Up 7.3% in AprilHeron Therapeutics, Inc. (NASDAQ:HRTX - Get Free Report) was the target of a large growth in short interest in April. As of April 30th, there was short interest totalling 27,290,000 shares, a growth of 7.3% from the April 15th total of 25,430,000 shares. Based on an average trading volume of 2,350,000 shares, the days-to-cover ratio is presently 11.6 days.May 12, 2024 | americanbankingnews.comHeron Therapeutics' (HRTX) Buy Rating Reaffirmed at Needham & Company LLCMay 11, 2024 | marketbeat.comHeron Therapeutics, Inc. (NASDAQ:HRTX) Shares Bought by Monaco Asset Management SAMMonaco Asset Management SAM grew its stake in shares of Heron Therapeutics, Inc. (NASDAQ:HRTX - Free Report) by 219.5% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 2,226,475 shares of the biotechnology coMay 11, 2024 | americanbankingnews.comNorthland Capmk Equities Analysts Raise Earnings Estimates for Heron Therapeutics, Inc. (NASDAQ:HRTX)May 10, 2024 | marketbeat.comQ2 2024 EPS Estimates for Heron Therapeutics, Inc. Raised by Northland Capmk (NASDAQ:HRTX)Heron Therapeutics, Inc. (NASDAQ:HRTX - Free Report) - Equities research analysts at Northland Capmk lifted their Q2 2024 earnings estimates for shares of Heron Therapeutics in a research report issued to clients and investors on Wednesday, May 8th. Northland Capmk analyst C. Byrnes now anticipatMay 9, 2024 | finance.yahoo.comHeron Therapeutics, Inc. (NASDAQ:HRTX) Just Released Its First-Quarter Earnings: Here's What Analysts ThinkMay 8, 2024 | finance.yahoo.comHeron Therapeutics, Inc. (NASDAQ:HRTX) Q1 2024 Earnings Call TranscriptMay 8, 2024 | marketbeat.comHeron Therapeutics (NASDAQ:HRTX) Rating Reiterated by Needham & Company LLCNeedham & Company LLC reiterated a "buy" rating and set a $5.00 price objective on shares of Heron Therapeutics in a research note on Wednesday.May 8, 2024 | finance.yahoo.comHeron Therapeutics Inc (HRTX) Q1 2024 Earnings Call Transcript Highlights: Significant ...May 8, 2024 | finance.yahoo.comHeron Therapeutics First Quarter 2024 Earnings: Beats ExpectationsMay 7, 2024 | finanznachrichten.deHeron Therapeutics, Inc.: Heron Therapeutics Announces First Quarter 2024 Financial Results and Highlights Recent Corporate UpdatesMay 7, 2024 | markets.businessinsider.comHeron Therapeutics Inc. Q1 Loss decreases, beats estimatesMay 7, 2024 | msn.comHeron Therapeutics GAAP EPS of -$0.02, revenue of $34.67MMay 7, 2024 | finance.yahoo.comHeron Therapeutics Inc (HRTX) Q1 2024 Earnings Overview: Surpasses Revenue EstimatesMay 7, 2024 | prnewswire.comHeron Therapeutics Announces First Quarter 2024 Financial Results and Highlights Recent Corporate UpdatesMay 7, 2024 | markets.businessinsider.comHeron Therapeutics earnings preview: what to expectApril 30, 2024 | marketbeat.comHeron Therapeutics (HRTX) Scheduled to Post Quarterly Earnings on TuesdayHeron Therapeutics (NASDAQ:HRTX) will be releasing earnings before the market opens on Tuesday, May 7, Zacks reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=588518)April 25, 2024 | finance.yahoo.comHeron Therapeutics, Inc.'s (NASDAQ:HRTX) Profit OutlookApril 25, 2024 | marketbeat.comEquities Analysts Offer Predictions for Heron Therapeutics, Inc.'s Q1 2024 Earnings (NASDAQ:HRTX)Heron Therapeutics, Inc. (NASDAQ:HRTX - Free Report) - Research analysts at Capital One Financial issued their Q1 2024 earnings per share (EPS) estimates for shares of Heron Therapeutics in a report released on Tuesday, April 23rd. Capital One Financial analyst T. Chiang forecasts that the biotecApril 24, 2024 | prnewswire.comHeron Therapeutics to Report First Quarter 2024 Financial Results on Tuesday, May 7, 2024April 23, 2024 | msn.comCapital One Initiates Coverage of Heron Therapeutics (HRTX) with Overweight RecommendationApril 23, 2024 | marketbeat.comHeron Therapeutics (NASDAQ:HRTX) Coverage Initiated at Capital One FinancialCapital One Financial started coverage on Heron Therapeutics in a research report on Tuesday. They set an "overweight" rating and a $6.00 price objective for the company.April 16, 2024 | seekingalpha.comHeron Therapeutics: Zynrelef Potentially Eases Shareholder PainApril 12, 2024 | nasdaq.comCommit To Buy Heron Therapeutics At $2, Earn 22.4% Annualized Using OptionsApril 11, 2024 | prnewswire.comHeron Therapeutics to Host Investor Day on May 15, 2024 in New York CityApril 1, 2024 | marketbeat.comCongress Park Capital LLC Purchases 1,209,500 Shares of Heron Therapeutics, Inc. (NASDAQ:HRTX)Congress Park Capital LLC increased its position in shares of Heron Therapeutics, Inc. (NASDAQ:HRTX - Free Report) by 205.3% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 1,798,650 shares of the biotechnology company's stoMarch 28, 2024 | prnewswire.comHeron Therapeutics Announces Presentation at the 23rd Annual Needham Virtual Healthcare ConferenceMarch 21, 2024 | marketbeat.comHeron Therapeutics (NASDAQ:HRTX) Shares Pass Above Two Hundred Day Moving Average of $1.67Heron Therapeutics (NASDAQ:HRTX) Stock Passes Above 200 Day Moving Average of $1.67March 16, 2024 | ca.finance.yahoo.comHRTX Apr 2024 1.500 callMarch 14, 2024 | finance.yahoo.comHeron Therapeutics Full Year 2023 Earnings: Beats ExpectationsMarch 14, 2024 | marketwatch.comHeron Therapeutics Soars After 4Q Earnings BeatMarch 13, 2024 | theglobeandmail.comBiotech Finds Mid-Week Success Following Q4 Earnings ReleaseMarch 13, 2024 | markets.businessinsider.comWhy Is Postoperative Pain Focused Heron Therapeutics Stock Trading Higher On Wednesday?March 13, 2024 | finance.yahoo.comQ4 2023 Heron Therapeutics Inc Earnings CallMarch 13, 2024 | finance.yahoo.comHeron Therapeutics, Inc. (NASDAQ:HRTX) Q4 2023 Earnings Call TranscriptMarch 13, 2024 | marketbeat.comHeron Therapeutics (NASDAQ:HRTX) Given New $5.00 Price Target at Needham & Company LLCNeedham & Company LLC increased their target price on shares of Heron Therapeutics from $4.00 to $5.00 and gave the company a "buy" rating in a research note on Wednesday.March 12, 2024 | finance.yahoo.comHeron Therapeutics Announces Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Corporate UpdatesMarch 12, 2024 | finance.yahoo.comHeron Therapeutics Inc (HRTX) Exceeds Full-Year Revenue Guidance for 2023March 12, 2024 | marketbeat.comHeron Therapeutics, Inc. (NASDAQ:HRTX) Shares Acquired by Adage Capital Partners GP L.L.C.Adage Capital Partners GP L.L.C. raised its holdings in shares of Heron Therapeutics, Inc. (NASDAQ:HRTX - Free Report) by 100.0% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 2,000,000 shares of the biotechnoloMarch 11, 2024 | msn.comHeron Therapeutics Q4 2023 Earnings PreviewMarch 11, 2024 | markets.businessinsider.comWhat Wall Street expects from Heron Therapeutics's earningsMarch 11, 2024 | benzinga.comPreview: Heron Therapeutics's EarningsMarch 5, 2024 | marketbeat.comHeron Therapeutics (HRTX) to Release Quarterly Earnings on TuesdayHeron Therapeutics (NASDAQ:HRTX) will be releasing earnings after the market closes on Tuesday, March 12, Zacks reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=571447)February 28, 2024 | finance.yahoo.comHeron Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results On Tuesday, March 12, 2024February 28, 2024 | prnewswire.comHeron Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results On Tuesday, March 12, 2024February 24, 2024 | msn.comHeron Therapeutics (HRTX) Price Target Increased by 18.52% to 6.80February 22, 2024 | benzinga.comHeron Therapeutics Stock (NASDAQ:HRTX), Short Interest ReportFebruary 17, 2024 | marketbeat.comHeron Therapeutics, Inc. (NASDAQ:HRTX) Shares Sold by D.A. Davidson & CO.D.A. Davidson & CO. decreased its holdings in shares of Heron Therapeutics, Inc. (NASDAQ:HRTX - Free Report) by 84.2% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 40,600 shares of the biotechnology comp Get Heron Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for HRTX and its competitors with MarketBeat's FREE daily newsletter. Email Address Obama’s Forever Term [exposed] (Ad)America’s Last Election New documentary, America’s Last Election, reveals the true (and terrifying) story of how the D.C. establishment has engineered a brutal new crisis that could hand them permanent power. Power they will use to reshape America to their dark, dystopian vision. Start streaming it now at no cost here HRTX Media Mentions By Week HRTX Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. HRTX News Sentiment▼0.820.52▲Average Medical News Sentiment HRTX News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. HRTX Articles This Week▼102▲HRTX Articles Average Week Get Heron Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for HRTX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Korro Bio News Today Biomea Fusion News Today Annexon News Today Lexicon Pharmaceuticals News Today Neurogene News Today Mersana Therapeutics News Today Corbus Pharmaceuticals News Today Esperion Therapeutics News Today PepGen News Today Revance Therapeutics News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:HRTX) was last updated on 5/18/2024 by MarketBeat.com Staff From Our PartnersShocking $16T Elon Musk Crypto LeakCrypto 101 MediaCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingMake this ONE trade on Tuesday at 2 p.m. EST!Monument Traders AllianceThe Presidential candidate you should REALLY be worried aboutStansberry ResearchProtect Your Bank Account Before It’s Too LateWeiss RatingsForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressWhat’s Really Next for America…Porter & CompanyHe called Apple at $1.49 and now he says: “Buy these 6 AI stocks.”InvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Heron Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
